In univariable analysis, factors associated with an increased risk of MBM development were T-stage at primary tumor diagnosis, metastatic stage, plasma levels of S100B, plasma levels of LDH, and first-line treatment at advanced melanoma diagnosis. The gene discussed is S100B; the disease is melanoma.